CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for VBI Vaccines Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

VBI Vaccines Inc
160 Second Street, Cambridge
Phone: (617) 830-3031p:617 830-3031 CAMBRIDGE, MA  02142  United States Ticker: VBIVVBIV
Business Summary
VBI Vaccines Inc. is a commercial stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Steven H.Gillis 70 5/1/2016 5/1/2016
President, Chief Executive Officer, Director Jeffrey R.Baxter 61 5/1/2016 5/1/2016
Chief Financial Officer, Director, Head of Corporate Development NellBeattie 35 4/10/2023 9/1/2017
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Valley High Ventures Ltd 625 Howe St Suite 1280 VANCOUVER BC Canada
VBI Vaccines Inc 222 3rd St Ste 2241 CAMBRIDGE MA United States
VBI Vaccines 245 First Street Cambridge MA United States

Business Names
Business Name
VAC
Variation Biotechnologies
Variation Biotechnologies (US), Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 131 (As of 12/31/2023)
Outstanding Shares: 28,432,275 (As of 4/16/2024)
Shareholders: 247
Stock Exchange: NASD
Fax Number: +972 89480660


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, April 25, 2024